# Audience Intelligence: Vertigo relief app

Adults (skewing female and older) suffering recurrent positional vertigo/BPPV, plus ENT clinics, audiologists, and vestibular physiotherapists who could recommend or white-label the app for between-visit home care. is the first audience because the report already names a repeated pain, reachable channels, and a validation test that can be run before software is complete.

## Segments
- **Adults (skewing female and older) suffering recurrent positional vertigo/BPPV, plus ENT clinics, audiologists, and vestibular physiotherapists who could recommend or white-label the app for between-visit home care.**: BPPV is the most common vestibular disorder, yet sufferers face long waits for ENT/vestibular specialists and struggle to perform repositioning maneuvers like the Epley correctly at home from static diagrams. Without guided head-positioning, episode tracking, and recurrence coaching, patients self-treat incorrectly, relapse (recurrence occurs in roughly half of cases), and miss daily activities. Trigger: BPPV is the most frequent vestibular disorder, with cumulative lifetime prevalence reported between 2.4% and 10%, higher in women (about 3.2% vs 1.6% in men) and rising with age, per population-based epidemiology studies indexed on NIH/PMC. Budget signal: Freemium consumer subscription (core maneuver guides free; advanced tracking, history export, and reminders behind a monthly/annual plan) plus a B2B clinic tier where ENT/audiology/physio practices license the app for patient home programs.
- **Budget owner who feels the operational cost of the broken workflow.**: Regulatory and medical-claims risk: positioning the app as treating or curing BPPV can trigger FDA software-as-a-medical-device scrutiny and liability; marketing must stay within wellness/educational claims and carry medical disclaimers. Trigger: AI-assisted product work and managed infrastructure reduce the first-version cost. Budget signal: $49-$499/month
- **Hands-on operator willing to pilot a narrow tool before a full rollout.**: Clinical safety risk: the Epley maneuver is unsafe for some users (neck/back disease, vascular conditions, retinal detachment) and self-diagnosis may miss serious causes of vertigo such as stroke, so robust screening and escalation prompts are essential. Trigger: Freemium consumer subscription (core maneuver guides free; advanced tracking, history export, and reminders behind a monthly/annual plan) plus a B2B clinic tier where ENT/audiology/physio practices license the app for patient home programs. Budget signal: $99-$1,000/year add-on
- **Adults (skewing female and older) suffering recurrent positional vertigo/BPPV, plus ENT clinics, audiologists, and vestibular physiotherapists who could recommend or white-label the app for between-visit home care. who still run the workflow in spreadsheets, generic docs, email, or chat threads.**: BPPV is the most common vestibular disorder, yet sufferers face long waits for ENT/vestibular specialists and struggle to perform repositioning maneuvers like the Epley correctly at home from static diagrams. Without guided head-positioning, episode tracking, and recurrence coaching, patients self-treat incorrectly, relapse (recurrence occurs in roughly half of cases), and miss daily activities. Trigger: The wedge is specific enough to test without claiming the whole market. Budget signal: Custom

## Channels
- **Reddit / forums**: Look for complaints, workarounds, and repeated questions. First move: Post a problem teardown for Consumer digital health for vestibular disorders, specifically BPPV and dizziness self-management, within the broader telerehabilitation and digital therapeutics space. and ask how people solve it today.
- **Launch communities**: Launch traction shows whether the promise is legible. First move: Ship a narrow demo and watch which promise gets clicks.
- **Review and alternative pages**: Pricing and alternatives expose buyer objections. First move: Write an alternatives page that owns one narrow use case.
- **Community pain posts**: Use communities and forums where Adults (skewing female and older) suffering recurrent positional vertigo/BPPV, plus ENT clinics, audiologists, and vestibular physiotherapists who could recommend or white-label the app for between-visit home care. already describe the painful workflow. First move: Problem teardown, interview ask, and short demo clip
- **Direct outreach**: Direct conversations are the fastest way to verify budget ownership and switching cost. First move: Concierge pilot offer with a manually prepared sample

## Intent Keywords
`vertigo workflow`, `relief validation`, `vertigo ai`, `relief automation`, `digital-health`, `vestibular`, `BPPV`, `telehealth`, `mobile-app`, `Consumer digital health for vestibular disorders, specifically BPPV and dizziness self-management, within the broader telerehabilitation and digital therapeutics space.`

## Messaging Angles
- Vertigo relief app should be tested as a narrow first-win workflow for Adults (skewing female and older) suffering recurrent positional vertigo/BPPV, plus ENT clinics, audiologists, and vestibular physiotherapists who could recommend or white-label the app for between-visit home care..
- Replace a narrow workflow that reaches value without configuration-heavy onboarding. with a focused first-win workflow.
- Promise proof around problem resonance: 5+ calls or 10+ detailed replies..
- De-risk adoption with concierge review or paid template.

## Objections
- Regulatory and medical-claims risk: positioning the app as treating or curing BPPV can trigger FDA software-as-a-medical-device scrutiny and liability; marketing must stay within wellness/educational claims and carry medical disclaimers.
- Clinical safety risk: the Epley maneuver is unsafe for some users (neck/back disease, vascular conditions, retinal detachment) and self-diagnosis may miss serious causes of vertigo such as stroke, so robust screening and escalation prompts are essential.
- Crowded niche with several established free and low-cost competitors and inherently low willingness-to-pay for an episodic, often self-resolving condition, making retention and recurring revenue difficult.
- Needs real buyer access, not only desk research.
- Needs proof of budget or repeated urgency.
- Needs a crisp wedge before broad product work starts.